Staff Profile
Dr Simon Bomken
MRC Clinician Scientist & Honorary Consultant
- Email: s.n.bomken@ncl.ac.uk
- Telephone: +44 (0) 191 208 4300
- Fax: +44 (0) 191 208 4301
- Address: MRC Clinician Scientist & Honorary Consultant Paediatric Oncologist
Wolfson Childhood Cancer Research Centre
Translational & Clinical Research Institute
Faculty of Medical Sciences
Newcastle University
I am an MRC Clinician Scientist and Honorary Consultant Paediatric Oncologist, providing a clinical service for young people with lymphoma or Langerhans cell histiocytosis at the Great North Children's Hospital, Newcastle.
Qualifications
2015 CCT Paediatrics (Paediatric Oncology)
2013 PhD, Newcastle University
2005 Membership of the Royal College of Paediatrics and Child Health, UK
2002 MBBS (Hons), Newcastle University
1999 BMedSci (Hons), Newcastle University
Memberships
Children's Cancer & Leukaemia Group (CCLG) NHL Interest Group Chair
European Hematology Association Pediatric Scientific Working Group
European Intergroup Collaboration for Childhood Non-Hodgkin Lymphoma (EICNHL)/SIOPE
International BFM Study Group - Genetic variation task force
NCRI Children's NHL subgroup
NCRI Lymphoma Science subgroup
Honours and Awards
2014 Lindau Nobel Laureate meeting alumnus, Royal Society nominee
2002 Mona McNaughton Prize - MBBS (Hons) final examination results 2002
1998 Wolfson Scholar - BMedSci (Hons)
Research Interests
Together with Dr Chris Bacon I run the Lymphoma Research Group within the Wolfson Childhood Cancer Research Centre and collaborate closely with Prof Vikki Rand at the National Horizon's Centre, Teesside University. Our aim is to deeply characterise paediatric B-cell non-Hodgkin lymphoma to provide a comprehensive understanding of disease initiation and evolution in response to therapy. My particular interests include understanding the molecular drivers of therapy resistance and the role that clonal evolution has to play in this clinically important phenomenon. Using sporadic Burkitt lymphoma as our principle disease, we are studying the genetic, transcriptomic and clonal changes which occur in response to therapeutic pressure within patient-derived xenograft models. Through understanding the drivers of clonal evolution we want to be able to predict patients more likely to develop therapy resistance and develop treatment strategies to target key resistance mechanisms.
I also work closely with UK and European colleagues (iBFM, EICNHL, ESID) to develop our understanding of development of lymphoid malignancy in children with inherited immune deficiency or DNA repair disorders and provide the paediatric clinical service for Langerhans cell histiocytosis and collaborate with Newcastle Human Dendritic Cell Laboratory (http://www.hudendritic.org/) run by Professor Matt Collin.
Funding - Current Projects
MRC Clinician Scientist Fellowship - Clonal heterogeneity and therapy resistance in Burkitt lymphoma
EU/Innovative Medicines Initiative
The Good Will Cause
North of England Children's Cancer Research Fund
Funding - Training
Sir Bobby Robson Foundation Clinical Fellow
ACF/ACL posts funded by NIHR
MRC Centenary Early Career Award
MRC Clinical Research Training Fellowship
I supervise undergraduate, masters and PhD students within the Wolfson Childhood Cancer Research Centre, as well as providing clinical teaching for medical students within the Great North Children's Hospital. I lecture on Cancer Stem Cells, Heterogeneity and Evolution within the Biomedical Sciences undergraduate degree programme.
I have contributed a chapter on clinical research to the recently published MRCPCH Science of Paediatrics Mastercourse book for candidates of the Royal College of Paediatrics and Child Health membership exam. I am also currently revising chapters on childhood lymphoma and tumour lysis syndrome for the second edition of the Oxford University Handbook of Paediatric Haematology and Oncology.
- Newman AM, Zaka M, Zhou P, Blain AE, Erhorn A, Barnard A, Crossland RE, Wilkinson S, Enshaei A, De Zordi J, Harding F, Taj M, Wood KM, Televantou D, Turner SD, Burke GAA, Harrison CJ, Bomken S, Bacon CM, Rand V. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. Leukemia 2021, 36, 781-789.
- Forde S, Matthews JD, Jahangiri L, Lee LC, Prokoph N, Malcolm TIM, Giger OT, Bell N, Blair H, O'Marcaigh A, Smith O, Kenner L, Bomken S, Burke GAA, Turner SD. Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy. British Journal of Haematology 2021, 192(2), 354-365.
- Taj MM, Maecker-Kolhoff B, Ling R, Bomken S, Burkhardt B, Chiang AKS, Csoka M, Füreder A, Haouy S, Lazic J, Miakova N, Minard-Colin V, Turner SD, Uyttebroeck A, Attarbaschi A. Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 pediatric patients. British Journal of Haematology 2021, (ePub ahead of Print).
- Wolfs TFW, Attarbaschi A, Balduzzi A, Bernardo ME, Bomken S, Borkhardt A, Bourquin JP, Dufour C, Gennery A, Grainger J, Hasle H, Hrusak O, Izraeli S, Mechinaud F, Trka J, Vormoor J. COVID-19 - Impact on childhood haematology patients. Hemasphere 2020, 4(5), e465.
- Prunotto G, Offor UT, Samarasinghe S, Wynn R, Vora A, Carpenter B, Gowdy C, McHugh K, Windebank KP, Rovelli AM, Slatter MA, Gennery AR, Veys P, Bacon CM, Bomken S, Lucchini G. HSCT provides effective treatment for lymphoproliferative disorders in children with primary immunodeficiency. Journal of Allergy and Clinical Immunology 2020, 146(2), 447-450.
- Offor UT, Bacon CM, Roberts J, Powell J, Brodlie M, Wood K, Windebank KP, Flett J, Hewitt T, Rand V, Hasan A, Parry G, Gennery AR, Reinhardt Z, Bomken S. Transplantation For Congenital Heart Disease Is Associated With An Increased Risk Of Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder In Children. Journal of Heart and Lung Transplantation 2020, 35(5), 24-32.
- Pearson ADJ, Scobie N, Norga K, Ligas F, Chiodin D, Burke A, Minard-Colin V, Adamson P, Marshall LV, Balakumaran A, Benettaib B, Bhargava P, Bollard CM, Bolotin E, Bomken S, Buechner J, Burkhardt B, Caron H, Copland C, Demolis P, Egorov A, Farhan M, Zugmaier G, Gross T, Horton-Taylor D, Klapper W, Lesa G, Marcus R, Miles RR, Nottage K, Pacaud L, Ricafort R, Schrappe M, Sterba J, Vezan R, Weiner S, Kim SY, Reaman G, Vassal G. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. European Journal of Cancer 2019, 110, 74-85.
- Zhou P, Blain AE, Newman AM, Zaka M, Chagaluka G, Adlar F, Offor UT, Broadbent C, Chaytor L, Whitehead A, Hall A, O'Connor H, Van Noorden S, Lampert I, Bailey S, Molyneux E, Bacon CM, Bomken S, Rand V. Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. Blood Advances 2019, 3(14), 2118-2127.
- Bomken S, van der Werff Ten Bosch J, Attarbaschi A, Bacon CM, Borkhardt A, Boztug K, Fischer U, Hauck F, Kuiper RP, Lammens T, Loeffen J, Neven B, Pan-Hammarstrom Q, Quinti I, Seidel MG, Warnatz K, Wehr C, Lankester AC, Gennery AR. Current Understanding and Future Research Priorities in Malignancy Associated With Inborn Errors of Immunity and DNA Repair Disorders: The Perspective of an Interdisciplinary Working Group. Frontiers in Immunology 2018, 9, 2912.
- Elder A, Bomken S, Wilson I, Blair HJ, Cockell S, Ponthan F, Dormon K, Pal D, Heidenreich O, Vormoor J. Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia. Leukemia 2017, 31, 2577-2586.
- Milne P, Bigley V, Bacon CM, Néel A, McGovern N, Bomken S, Haniffa M, Diamond EL, Durham BH, Visser J, Hunt D, Gunawardena H, Macheta M, McClain KL, Allen C, Abdel-Wahab O, Collin M. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim Chester disease in adults. Blood 2017, 130(2), 167-175.
- Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma. Haematologica 2017, 102(7), 1247-1257.
- Mellgren K, Attarbaschi A, Abla O, Alexander S, Bomken S, Bubanska E, Chiang A, Csóka M, Fedorova A, Kabickova E, Kapuscinska-Kemblowska L, Kobayashi R, Krenova Z, Meyer-Wentrup F, Miakova N, Pillon M, Plat G, Uyttebroeck A, Williams D, Wróbel G, Kontny U. Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases. Annals of Hematology 2016, 95(8), 1295-1305.
- Attarbaschi A, Carraro E, Abla O, Barzilai-Birenboim S, Bomken S, Brugieres L, Bubanska E, Burkhardt B, Chiang AK, Csoka M, Fedorova A, Jazbec J, Kabickova E, Krenova Z, Lazic J, Loeffen J, Mann G, Niggli F, Miakova N, Osumi T, Ronceray L, Uyttebroeck A, Williams D, Woessmann W, Wrobel G, Pillon M. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. Haematologica 2016, 101(12), 1581-1591.
- Scherr M, Elder A, Battmer K, Barzan D, Bomken S, Ricke-Hoch M, Schröder A, Venturini L, Blair HJ, Vormoor J, Ottmann O, Ganser A, Pich A, Hilfiker-Kleiner D, Heidenreich O, Eder M. Differential expression of miR-17~92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia. Leukemia 2014, 28, 554-565.
- Rehe K, Wilson K, Bomken S, Williamson D, Irving J, den Boer ML, Stanulla M, Schrappe M, Hall AG, Heidenreich O, Vormoor J. Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations. EMBO Molecular Medicine 2013, 5(1), 38-51.
- Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, Blair H, Bacon CM, Vormoor J, Heidenreich O. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia 2013, 27(3), 718-721.
- Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. British Journal of Cancer 2010, 103(4), 439-445.
- le Viseur C, Hotfilder M, Bomken S, Wilson K, Röttgers S, Schrauder A, Rosemann A, Irving JAE, Stam R, Shultz L, Harbott J, Jürgens H, Schrappe M, Pieters R, Vormoor HJ. In Childhood Acute Lymphoblastic Leukemia, Blasts at Different Stages of Immunophenotypic Maturation Have Stem Cell Properties. Cancer Cell 2008, 14(1), 47-58.